The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...

There are around 17,500 people with sickle cell disease ... best care to patients fast,” said Nice chief executive Dr Samantha Roberts. Ludovic Fenaux, senior vice president at Vertex ...

Gallbladder issues are a frequent but manageable complication of sickle cell disease. Awareness of the symptoms and risk factors, combined with regular medical care, can help patients address ...

It is not known how much the NHS will pay Vertex ... form of the disease. "[It] could be absolutely transformative - it could enable patients to live free from the fear of sickle cell crises ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

In addition to the prolonged pain and suffering endured by sickle cell patients, a Washington University School of Medicine study has concluded that there could be a significant impact on cognitive ...

It is not known how much the NHS will pay Vertex for the treatment ... facing a severe form of the disease. "[It] could be absolutely transformative - it could enable patients to live free from the ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

LONDON, January 31, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access ...